Advanced biliary tract cancer (BTC) is a tough nut to crack. Doctors often turn to second-line treatments like 5-fluorouracil (5FU) and liposomal irinotecan when first-line therapies fail. These drugs have shown promise in improving survival rates. But what if we could make them even more effective? That’s where nivolumab comes in.

Nivolumab is an immunotherapy drug that helps the body’s immune system fight cancer. In a recent multi-center trial, researchers combined nivolumab with 5FU and liposomal irinotecan to see if this triple threat could work better than the chemo duo alone.

The study, called BilT03, was split into two phases. Phase 1b was about finding the right dose of nivolumab to use with the chemo drugs. Phase 2 was to test how well the combo worked in patients whose cancer had progressed after initial treatment.

The results were encouraging. The triple therapy seemed to work well, with many patients showing no signs of cancer growth for a good while. Plus, the side effects weren’t too harsh.

This is great news for people with advanced BTC. Having more treatment options can make a big difference. But it’s important to remember that this is just one study. More research is needed to confirm these findings.

New Hope for Advanced Biliary Tract Cancer: Combining Nivolumab with Chemotherapy

Actions